Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Return on Equity (2016 - 2026)

Champions Oncology has reported Return on Equity over the past 16 years, most recently at 0.55% for Q1 2026.

  • Quarterly results put Return on Equity at 0.55% for Q1 2026, down 264.0% from a year ago — trailing twelve months through Jan 2026 was 0.55% (down 264.0% YoY), and the annual figure for FY2025 was 5.03%, up 1036.0%.
  • Return on Equity for Q1 2026 was 0.55% at Champions Oncology, down from 0.63% in the prior quarter.
  • Over the last five years, Return on Equity for CSBR hit a ceiling of 9.9% in Q1 2024 and a floor of 9.66% in Q4 2023.
  • Median Return on Equity over the past 5 years was 0.04% (2022), compared with a mean of 0.24%.
  • Biggest five-year swings in Return on Equity: tumbled -967bps in 2023 and later surged 1029bps in 2024.
  • Champions Oncology's Return on Equity stood at 0.01% in 2022, then tumbled by -81262bps to 9.66% in 2023, then skyrocketed by 65bps to 3.43% in 2024, then surged by 118bps to 0.63% in 2025, then plummeted by -188bps to 0.55% in 2026.
  • The last three reported values for Return on Equity were 0.55% (Q1 2026), 0.63% (Q4 2025), and 0.8% (Q3 2025) per Business Quant data.